Cargando…
Evaluation of risk for graft-versus-host disease in children who receive less than the full doses of mini-dose methotrexate for graft-versus-host disease prophylaxis in allogeneic hematopoietic stem cell transplantation
PURPOSE: The use of cyclosporine and mini-dose methotrexate (MTX) is a common strategy for graft-versus-host disease (GVHD) prophylaxis in allogeneic transplants. We investigated whether patients who receive fewer than the planned MTX doses are at increased risk for GVHD. METHODS: The study cohort i...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Pediatric Society
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859882/ https://www.ncbi.nlm.nih.gov/pubmed/24348662 http://dx.doi.org/10.3345/kjp.2013.56.11.490 |
_version_ | 1782295465746759680 |
---|---|
author | Yum, Sook Kyung Choi, Hye-Yoon Lee, Jae Wook Jang, Pil-Sang Chung, Nack-Gyun Jeong, Dae-Chul Cho, Bin Kim, Hack-Ki |
author_facet | Yum, Sook Kyung Choi, Hye-Yoon Lee, Jae Wook Jang, Pil-Sang Chung, Nack-Gyun Jeong, Dae-Chul Cho, Bin Kim, Hack-Ki |
author_sort | Yum, Sook Kyung |
collection | PubMed |
description | PURPOSE: The use of cyclosporine and mini-dose methotrexate (MTX) is a common strategy for graft-versus-host disease (GVHD) prophylaxis in allogeneic transplants. We investigated whether patients who receive fewer than the planned MTX doses are at increased risk for GVHD. METHODS: The study cohort included 103 patients who received allogeneic transplants at the Department of Pediatrics of The Catholic University of Korea College of Medicine, from January 2010 to December 2011. MTX was administered on days 1, 3, 6, and 11 after transplant at a dose of 5 mg/m(2) each. Within the cohort, 76 patients (74%) received all 4 doses of MTX [MTX(4) group], while 27 patients (26%) received 0-3 doses [MTX(0-3) group]. RESULTS: Although there was no difference in neutrophil engraftment between the 2 groups, platelet engraftment was significantly faster in the MTX(4) group (median, 15 days), compared to the MTX(0-3) group (median, 25 days; P=0.034). The incidence of grades II-IV acute GVHD was not different between the MTX(4) and MTX(0-3) groups (P=0.417). In the multivariate study, human leukocyte antigen mismatch was the most significant factor causing grades II-IV acute GVHD (P=0.002), followed by female donor to male recipient transplant (P=0.034). No difference was found between the MTX(4) and MTX (0-3) groups regarding grades III-IV acute GVHD, chronic GVHD, and disease-free survival. CONCLUSION: Our results indicate that deviations from the full dose schedule of MTX for GVHD prophylaxis do not lead to increased incidence of either acute or chronic GVHD. |
format | Online Article Text |
id | pubmed-3859882 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | The Korean Pediatric Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-38598822013-12-12 Evaluation of risk for graft-versus-host disease in children who receive less than the full doses of mini-dose methotrexate for graft-versus-host disease prophylaxis in allogeneic hematopoietic stem cell transplantation Yum, Sook Kyung Choi, Hye-Yoon Lee, Jae Wook Jang, Pil-Sang Chung, Nack-Gyun Jeong, Dae-Chul Cho, Bin Kim, Hack-Ki Korean J Pediatr Original Article PURPOSE: The use of cyclosporine and mini-dose methotrexate (MTX) is a common strategy for graft-versus-host disease (GVHD) prophylaxis in allogeneic transplants. We investigated whether patients who receive fewer than the planned MTX doses are at increased risk for GVHD. METHODS: The study cohort included 103 patients who received allogeneic transplants at the Department of Pediatrics of The Catholic University of Korea College of Medicine, from January 2010 to December 2011. MTX was administered on days 1, 3, 6, and 11 after transplant at a dose of 5 mg/m(2) each. Within the cohort, 76 patients (74%) received all 4 doses of MTX [MTX(4) group], while 27 patients (26%) received 0-3 doses [MTX(0-3) group]. RESULTS: Although there was no difference in neutrophil engraftment between the 2 groups, platelet engraftment was significantly faster in the MTX(4) group (median, 15 days), compared to the MTX(0-3) group (median, 25 days; P=0.034). The incidence of grades II-IV acute GVHD was not different between the MTX(4) and MTX(0-3) groups (P=0.417). In the multivariate study, human leukocyte antigen mismatch was the most significant factor causing grades II-IV acute GVHD (P=0.002), followed by female donor to male recipient transplant (P=0.034). No difference was found between the MTX(4) and MTX (0-3) groups regarding grades III-IV acute GVHD, chronic GVHD, and disease-free survival. CONCLUSION: Our results indicate that deviations from the full dose schedule of MTX for GVHD prophylaxis do not lead to increased incidence of either acute or chronic GVHD. The Korean Pediatric Society 2013-11 2013-11-27 /pmc/articles/PMC3859882/ /pubmed/24348662 http://dx.doi.org/10.3345/kjp.2013.56.11.490 Text en Copyright © 2013 by The Korean Pediatric Society http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Yum, Sook Kyung Choi, Hye-Yoon Lee, Jae Wook Jang, Pil-Sang Chung, Nack-Gyun Jeong, Dae-Chul Cho, Bin Kim, Hack-Ki Evaluation of risk for graft-versus-host disease in children who receive less than the full doses of mini-dose methotrexate for graft-versus-host disease prophylaxis in allogeneic hematopoietic stem cell transplantation |
title | Evaluation of risk for graft-versus-host disease in children who receive less than the full doses of mini-dose methotrexate for graft-versus-host disease prophylaxis in allogeneic hematopoietic stem cell transplantation |
title_full | Evaluation of risk for graft-versus-host disease in children who receive less than the full doses of mini-dose methotrexate for graft-versus-host disease prophylaxis in allogeneic hematopoietic stem cell transplantation |
title_fullStr | Evaluation of risk for graft-versus-host disease in children who receive less than the full doses of mini-dose methotrexate for graft-versus-host disease prophylaxis in allogeneic hematopoietic stem cell transplantation |
title_full_unstemmed | Evaluation of risk for graft-versus-host disease in children who receive less than the full doses of mini-dose methotrexate for graft-versus-host disease prophylaxis in allogeneic hematopoietic stem cell transplantation |
title_short | Evaluation of risk for graft-versus-host disease in children who receive less than the full doses of mini-dose methotrexate for graft-versus-host disease prophylaxis in allogeneic hematopoietic stem cell transplantation |
title_sort | evaluation of risk for graft-versus-host disease in children who receive less than the full doses of mini-dose methotrexate for graft-versus-host disease prophylaxis in allogeneic hematopoietic stem cell transplantation |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859882/ https://www.ncbi.nlm.nih.gov/pubmed/24348662 http://dx.doi.org/10.3345/kjp.2013.56.11.490 |
work_keys_str_mv | AT yumsookkyung evaluationofriskforgraftversushostdiseaseinchildrenwhoreceivelessthanthefulldosesofminidosemethotrexateforgraftversushostdiseaseprophylaxisinallogeneichematopoieticstemcelltransplantation AT choihyeyoon evaluationofriskforgraftversushostdiseaseinchildrenwhoreceivelessthanthefulldosesofminidosemethotrexateforgraftversushostdiseaseprophylaxisinallogeneichematopoieticstemcelltransplantation AT leejaewook evaluationofriskforgraftversushostdiseaseinchildrenwhoreceivelessthanthefulldosesofminidosemethotrexateforgraftversushostdiseaseprophylaxisinallogeneichematopoieticstemcelltransplantation AT jangpilsang evaluationofriskforgraftversushostdiseaseinchildrenwhoreceivelessthanthefulldosesofminidosemethotrexateforgraftversushostdiseaseprophylaxisinallogeneichematopoieticstemcelltransplantation AT chungnackgyun evaluationofriskforgraftversushostdiseaseinchildrenwhoreceivelessthanthefulldosesofminidosemethotrexateforgraftversushostdiseaseprophylaxisinallogeneichematopoieticstemcelltransplantation AT jeongdaechul evaluationofriskforgraftversushostdiseaseinchildrenwhoreceivelessthanthefulldosesofminidosemethotrexateforgraftversushostdiseaseprophylaxisinallogeneichematopoieticstemcelltransplantation AT chobin evaluationofriskforgraftversushostdiseaseinchildrenwhoreceivelessthanthefulldosesofminidosemethotrexateforgraftversushostdiseaseprophylaxisinallogeneichematopoieticstemcelltransplantation AT kimhackki evaluationofriskforgraftversushostdiseaseinchildrenwhoreceivelessthanthefulldosesofminidosemethotrexateforgraftversushostdiseaseprophylaxisinallogeneichematopoieticstemcelltransplantation |